Raphael Landovitz
Expertise in
1
conditions

Dr. Raphael Landovitz

Infectious Disease
UC Regents UCLA DMPG Century City
1399 Roxbury Dr Ste 100, 
Los Angeles, CA 
Expertise in
1
conditions
UC Regents UCLA DMPG Century City
1399 Roxbury Dr Ste 100, 
Los Angeles, CA 

Overview

Raphael Landovitz is an Infectious Disease provider in Los Angeles, California. Dr. Landovitz is highly rated in 1 condition, according to our data. His top areas of expertise are HIV/AIDS, Gonorrhea, Severe Acute Respiratory Syndrome (SARS), Chlamydia, and Tissue Biopsy.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Infectious Disease

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UC Regents UCLA DMPG Century City
1399 Roxbury Dr Ste 100, Los Angeles, CA 90035

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study
Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study
Enrollment Status: Completed
Publish Date: December 16, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
Enrollment Status: Completed
Publish Date: June 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

149 Total Publications

PrEP as a "Hidden Message": The Impact of Partner Dynamics on Oral PrEP Adherence Among Cisgender Women in Serodiscordant Relationships.
PrEP as a "Hidden Message": The Impact of Partner Dynamics on Oral PrEP Adherence Among Cisgender Women in Serodiscordant Relationships.
Journal: AIDS and behavior
Published: December 13, 2025
Similar Doctors
Jeffrey Klausner
Expertise in
15
conditions
Dr. Jeffrey Klausner
Infectious Disease
Expertise in
15
conditions
Dr. Jeffrey Klausner
Infectious Disease

UC Regents UCLA DMPG Century City

1399 Roxbury Dr Ste 100, 
Los Angeles, CA 
 (1.1 miles away)
310-557-2273
Languages Spoken:
English
See accepted insurances

Jeffrey Klausner is an Infectious Disease provider in Los Angeles, California. Dr. Klausner is highly rated in 15 conditions, according to our data. His top areas of expertise are Gonorrhea, Syphilis, Chlamydia, and HIV/AIDS.

Expertise in
9
conditions
Dr. Peter Ruane
Infectious Disease
Expertise in
9
conditions
Dr. Peter Ruane
Infectious Disease

Peter J. Ruane M.D. Inc.

5901 W Olympic Blvd Ste 401, 
Los Angeles, CA 
 (3.2 miles away)
323-954-1022
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Peter Ruane is an Infectious Disease provider in Los Angeles, California. Dr. Ruane is highly rated in 9 conditions, according to our data. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

Expertise in
12
conditions
Dr. James A. Mckinnell
Infectious Disease
Expertise in
12
conditions
Dr. James A. Mckinnell
Infectious Disease

Torrance Health Association Inc.

2841 Lomita Blvd, 
Torrance, CA 
 (17.2 miles away)
310-784-6954
Experience:
22+ years
Languages Spoken:
English
See accepted insurances

James Mckinnell is an Infectious Disease provider in Torrance, California. Dr. Mckinnell has been practicing medicine for over 22 years is highly rated in 12 conditions, according to our data. His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), COVID-19, Sepsis, Multisystem Inflammatory Syndrome in Children (MIS-C), and Coronary Artery Bypass Graft (CABG).

Frequently Asked Questions about Dr. Raphael Landovitz

How do I make an appointment with Dr. Raphael Landovitz?

You can book an appointment with Dr. Raphael Landovitz by calling their office at 310-557-2273. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Raphael Landovitz a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Raphael Landovitz is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Raphael Landovitz specialize in?

While Dr. Raphael Landovitz is a Infectious Disease, they have specific expertise in HIV/AIDS, Gonorrhea, and Severe Acute Respiratory Syndrome (SARS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Raphael Landovitz participate in research or clinical trials?

Yes. Dr. Raphael Landovitz has published 149 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Raphael Landovitz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Raphael Landovitz accept my insurance?

Dr. Raphael Landovitz accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-557-2273 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Landovitz's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile